UPDATE: MLV Initiates Cytokinetics with Buy, $4 PT

MLV initiates its coverage on Cytokinetics CYTK with a Buy rating and a price target of $4 as the company approaches a pivotal stage in the development of CK-357 and Omecamtiv. MLV notes, "Through a unique molecular motors targeting approach, Cytokinetics, Inc. has successfully discovered and advanced two promising product candidates into clinical development: CK-357 for the treatment of skeletal muscle disorders, and omecamtiv mecarbil for the treatment of cardiac muscle disorders. We anticipate a number of clinical trial results in 2012 that we expect will determine the future direction of these programs and of Cytokinetics as well." CYTK closed at $1.09 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetInitiationIntraday UpdateAnalyst RatingsMLV
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!